Thus, inhibiting the O-GlcNAcylation-c-Myc-PD-L1 signaling axis could be a promising therapeutic strategy to stimulate anti-cancer T cell cytotoxicity, hence improving immunotherapy. Here, CD274 is linked to cancer.